Literature DB >> 7736528

Monoclonal antibodies and idiotypic network activation for ovarian carcinoma.

U Wagner1, J Reinsberg, S Schmidt, P Mallmann, J Schmolling, B Schultes, H Richter, H J Biersack, D Krebs.   

Abstract

Antibodies can be processed by the B- and T-cell systems and may lead to a selective activation of the immune system. The network structure of the immune system implicates the possibility of a selective immunization by the activation of idiotypic cascades. In a retrospective analysis, patients with advanced ovarian carcinoma, who had received MAb, against the cancer-associated antigen CA125 for diagnostic purposes, were analyzed for the production of anti-idiotypic antibodies, survival rate, and immunological effects. Furthermore, we started a prospective and randomized study for ovarian cancer patients, using a different antigen, TAG72, for the induction of idiotypic cascades. Our first results on 58 patients with advanced ovarian carcinomas showed that the induction of anti-idiotypic-antibodies against OC125 mimicking the TAA Class III CA125 leads to a prolongation of the survival rate, and, in extended stages, to an induction of antitumoral immunity, and that the induction of idiotypic cascades is also possible for different antigens like TAG72. Summarizing the activation of idiotypic network cascades seems to be a very effective way of intervention in the immune system of patients with advanced stages of ovarian carcinoma. A prospective study of the adjuvant approach seems to be necessary.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7736528     DOI: 10.1007/bf02789234

Source DB:  PubMed          Journal:  Cell Biophys        ISSN: 0163-4992


  5 in total

1.  Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network.

Authors:  U A Wagner; P F Oehr; J Reinsberg; S C Schmidt; H W Schlebusch; B Schultes; A Werner; G Prietl; D Krebs
Journal:  Biotechnol Ther       Date:  1992

2.  Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.

Authors:  M Wettendorff; D Iliopoulos; M Tempero; D Kay; E DeFreitas; H Koprowski; D Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

4.  Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection.

Authors:  J Reinsberg; A Heydweiller; U Wagner; K Pfeil; P Oehr; D Krebs
Journal:  Clin Chem       Date:  1990-01       Impact factor: 8.327

5.  Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

Authors:  H Koprowski; D Herlyn; M Lubeck; E DeFreitas; H F Sears
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

  5 in total
  1 in total

Review 1.  Antigen-specific active immunotherapy for ovarian cancer.

Authors:  Sterre T Paijens; Ninke Leffers; Toos Daemen; Wijnand Helfrich; H Marike Boezen; Ben J Cohlen; Cornelis Jm Melief; Marco de Bruyn; Hans W Nijman
Journal:  Cochrane Database Syst Rev       Date:  2018-09-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.